GSKMEX:GSKN 73 FCF Margin % is 9.15% as of Mar. 2026, which is 45% below its 10-year median of 16.49. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review. Among 958 Drug Manufacturers companies, GSK ranks better than 80.27% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GSK's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN16,782 Mil. GSK's Revenue for the
three
months ended in Mar. 2026 was MXN183,429 Mil. Therefore, GSK's FCF Margin % for the quarter that ended in Mar. 2026 was 9.15%.
The historical rank and industry rank for GSK's FCF Margin % or its related term are showing as below:
MEX:GSKN'
s FCF Margin % Range Over the Past 10 Years
Min: 11.38 Med: 16.49 Max: 26.67
Current: 14.61
During the past 13 years, the highest FCF Margin % of GSK was 26.67%. The lowest was 11.38%. And the median was 16.49%.
MEX:GSKN's FCF Margin % is ranked better than 80.27% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs MEX:GSKN: 14.61
GSK FCF Margin % Related Terms
GSK FCF Margin % Historical Data
* Premium members only.
The historical data trend for GSK's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GSKN vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, GSK's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's FCF Margin % distribution charts can be found below:
* The bar in red indicates where GSK's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (MEX:GSKN) has a FCF Margin % of 9.15% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GSK and its competitors. This is 45% below median its historical median of 16.49. Over the past decade, GSK's FCF Margin % has ranged from 11.38 to 26.67. According to the industry distribution chart, GSK ranks #189 out of 958 companies in the Drug Manufacturers industry, placing it in the top 19.7%.
Is GSK's FCF Margin % too high?
GSK's current FCF Margin % of 9.15% is 45% below median its 10-year median of 16.49. Over the past 10 years, this metric has ranged from a low of 11.38 to a high of 26.67. The Drug Manufacturers industry median FCF Margin % is 2.51. GSK's value of 9.15% is 264.5% above this industry median. Based on the distribution chart, GSK ranks #189 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #189 out of 958 companies for FCF Margin %. This places GSK in the top 20% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. GSK's value of 9.15% is 264.5% above this benchmark. Historically, GSK's own FCF Margin % has ranged from 11.38 to 26.67 over the past decade. While the company's 10-year median is 16.49 vs. the industry median of 2.51, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current FCF Margin % of 9.15% is 264.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current FCF Margin % is 9.15%, which is 45% below median its own 10-year median of 16.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current FCF Margin % is 9.15%, which is 45% below median its 10-year median of 16.49 and 264.5% above the Drug Manufacturers industry median of 2.51. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For GSK (MEX:GSKN), the current FCF Margin % is 9.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (MEX:GSKN) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82.
GuruFocus considers GSK to be Fairly Valued.
Key valuation signals for MEX:GSKN:
FCF Margin %: 9.15% (45% below median its 10-year median of 16.49)
GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
Industry Position: 264.5% above the Drug Manufacturers median (#189 of 958)
No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score
Get the complete analysis for MEX:GSKN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GSKN has been successfully added to your 
